Studies have validated that the concurrent use of ATP-competitive inhibitors to target the AKT/mTOR pathway and HER2 inhibitors can induce apoptosis in tumor cells and result in tumor shrinkage, with these effects being sustained over time. This evidence concerns the gene ERBB2 and neoplasm.